BioCurex, Inc.(fka BOCX)

[HALF FULL GLASS]

So Abbott jointly presented a non solid science?

Preliminary studies indicate that RECAF may provide good clinical sensitivity and specificity as a tumor marker," said William Brown, Ph.D., vice president, Diagnostic Assays and Systems Development, Abbott.  "Abbott's goal is to further develop this technology, incorporating it into future tests on our ARCHITECT® system, for use in cancer diagnosis and monitoring."

BioCurex and Abbott Jointly Present RECAF Results at International Cancer Congress